^{1}H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints

D. Bizzarri[1,2], M.J.T. Reinders[2,3], M. Beekman[1], P.E. Slagboom[1,4], BBMRI-NL[5] and E.B. van den Akker[1,2,3,#]

[1]Molecular Epidemiology, LUMC, Leiden, The Netherlands
[2] Leiden Computational Biology Center, LUMC, Leiden, The Netherlands
[3]Delft Bioinformatics Lab, TU Delft, Delft, The Netherlands
[4] Max Planck Institute for the Biology of Ageing, Cologne, Germany
[5] BBMRI-NL: https://www.bbmri.nl; see Consortium Banner Supplement S1

Material & correspondence (#)
Erik B. van den Akker, PhD; Leiden Computational Biology Center, Leiden University Medical Center, Leiden, The Netherlands; Einthovenweg 20, 2333 ZC, Leiden, The Netherlands; Tel: +31 (0)71 526 85 57; Fax: +31 (0)71 526 82 80; E-mail: e.b.van_den_akker@lumc.nl; website: http://www.lcbc.nl

ABSTRACT

Missing or incomplete phenotypic information can severely deteriorate the statistical power in epidemiological studies. High-throughput quantification of small-molecules in bio-samples, i.e. 'metabolomics', is steadily gaining popularity, as it is highly informative for various phenotypical characteristics. Here we aim to leverage metabolomics to impute missing data in clinical variables routinely assessed in large epidemiological and clinical studies. To this end, we have employed ~25,000 ^{1}H-NMR metabolomics samples from 28 Dutch cohorts collected within the BBMRI-NL consortium, to create 19 metabolomics-based predictors for clinical variables, including diabetes status ($AUC_{5\text{-Fold CV}}$ = 0.94) and lipid medication usage ($AUC_{5\text{-Fold CV}}$ = 0.90). Subsequent application in independent cohorts confirmed that our metabolomics-based predictors can indeed be used to impute a wide array of missing clinical variables from a single metabolomics data resource. In addition, application highlighted the potential use of our predictors to explore the effects of totally unobserved confounders in omics association studies. Finally, we show that our predictors can be used to explore risk factor profiles contributing to mortality in older participants. To conclude, we provide ^{1}H-NMR metabolomics-based models to impute clinical variables routinely assessed in epidemiological studies and illustrate their merit in scenarios when phenotypic variables are partially incomplete or totally unobserved.

INTRODUCTION

A major goal in biomedical research is to find faithful biomarkers of health, defined as accurate and reproducible assays that provide objective indications on the health of an individual and his/her risk of developing a disease over predefined time trajectory [1]. Over the years, many types of putative biomarkers have been proposed, ranging from environmental factors to biochemical assays, that may aid the diagnosis and prognostication of disease, including cardiovascular disease, cancer and immunological disorders. Many of these clinical variables, however, are costly or cumbersome to obtain, especially for more critical and frail participants, such as older individuals [2], [3]. Consequently, missing data frequently occurs in large epidemiological or clinical studies, potentially leading to a significant loss of statistical power, thus impeding biomarker research in studies of older individuals [4].

Missing phenotypic data can be handled in various ways. Often, analyses are either restricted to individuals or variables with complete data, which both may introduce potential biases [5]. Alternatively, missing data can be imputed using complete phenotypic variables [4], [6]–[8], yet these approaches work only satisfactory if the complete phenotypic variables are informative for the ones with missing observations. A third solution basically extents the second approach by leveraging informative omics data to impute missing phenotypic data. Particularly useful in this context are metabolite quantifications in minimally invasive biomaterials, such as urine, saliva or blood plasma, obtained with proton Nuclear Magnetic Resonance (^{1}H-NMR) assays [9]. Although this technique only captures a modest number of analytes, ^{1}H-NMR metabolomics data is frequently acquired in large-scale epidemiological studies, as it is a cost-efficient and reproducible data resource. The underlying motivation is that metabolite concentrations in blood seem to be direct readouts of various biological processes, incorporating cues of the environment as well as the host's genetic background, and hence may be regarded as intermediate phenotypes. Indeed, metabolomics has been shown to

capture information on the effect of drug treatments [10], disease status [11]–[14], functional and cognitive decline [15], and aging [16], [17]. In addition, several studies used the blood metabolome to predict single anthropometric measures, i.e. BMI [18], or other physiological characteristics, i.e. sex [19] or age [16]. However, it remains unclear whether the blood metabolome captured by ^{1}H-NMR could represent phenotypic information over a wider set of conventional clinical variables.

We hypothesize that a single set of blood metabolic markers combined in multiple algorithms may represent a range of conventional clinical variables. As a proof of concept, we generated metabolic surrogates for 20 variables of general clinical and epidemiological interest available in at least 6 of the cohorts collaborating in BBMRI-NL. Here we will designate these as conventional clinical variables and they comprehend physiological measures (sex, age, blood pressure, etc.), environmental exposures (current smoking, etc.), body composition measures (BMI, etc.), inflammatory factors (hsCRP), medication usage (lipids medication, etc.), blood composition (white cell counts, etc.) lipids metabolism (LDL-cholesterol, etc.) and cardiometabolic clinical endpoints (diabetes and metabolic syndrome). Acquiring data for all these variables is costly and requires sufficient biomaterial, meaning that not every study has collected the same set of data. We further explored these methods to establish metabolic surrogate values in the Leiden Longevity Study, which we used to showcase possible applications in epidemiological research. We showed the validity of the surrogates in an external cohort comparing them to the original values, we examined their association to further clinically valuable cardiometabolic health markers, and explored whether the metabolic surrogates associate, separately or combined, to all-cause mortality.





Figure 1: Study design. [A] Upper panel: Training of ^{1}H-NMR metabolomics-based predictors for routinely assessed phenotypic variables available in BBMRI.nl. This data set was created as a collaboration of 28 community and hospital-based cohorts that collected nuclear magnetic resonance (^{1}H-NMR) metabolomics data (Nightingale) for ~31,000 individuals. Upper panel left: Metabolomics-based predictors were trained using an *inner* loop of 5-fold Cross Validation (CV) (with 5 repetitions) for hyperparameter optimization and were evaluated in unseen data employing an *outer* loop of 5-fold CV or Leave-One-Biobank-Out-Validation (LOBOV). Upper panel right: using our models 19 different surrogate values can be derived from a single metabolomics data measurement to impute or complement a broad set of conventional clinical variables routinely assessed in epidemiological and clinical studies. Lower panel: Trained metabolomics-predictors were evaluated in two application scenarios using a held-out study, the Leiden Longevity Study [20]. This study is a two-generation family-based cohort consisting of highly aged parents (LLS-SIBS, N = 817, median age = 92 years) and their middle-aged offspring and the partners thereof (LLS-PAROFF, N = 2,280, median age = 59 years), for which we had access to additional detailed phenotypic information. Trained predictors were evaluated for their ability to reconstruct missing datapoints in an independent dataset (Application 1, lower left), to be used as confounder in Metabolome Wide Association Studies (Application 2, lower central), and to investigate and to explore determinants of health in older individuals (Application 3, lower right). **[B]** Groupings of phenotypic variables routinely assessed in epidemiological and clinical studies for which data was available in BBMRI-NL. Continuous variables are dichotomized at levels generally accepted to confer an increased risk for cardio-metabolic endpoints. As various cutoffs on chronological age are in use, in part reflecting the highly non-linear relation between chronological age and disease risk, we choose to split chronological age in three categories (I 'young': < 45 years [TRUE/FALSE]; II 'middle-aged': ≥ 45 years [TRUE/FALSE]] and III 'old': < 65 years [TRUE/FALSE]]; ≥ 65 years). We integrated Body Mass Index, waist circumference and sex into one sex-specific measure of 'obesity'. Similarly, we integrated diastolic blood pressure (DBP) and systolic blood pressure to arrive at one variable 'high pressure'. Overall, we obtain data for 20 dichotomous phenotypic variables. Colors indicate groupings.

Through the paper, we indicated some of the clinical variables with the following abbreviation: BMI=Body Mass Index, med=medication, e.g.: lipid or blood pressure lowering medication, hsCRP=high-sensitivity C-Reactive Protein, eGFR=estimated Glomerular Filtration Rate, chol=cholesterol, hgb=haemoglobin, wbc=white blood cells.

RESULTS

^{1}H-NMR metabolomics can be used to successfully predict 19 out of 20 clinical variables routinely measured in epidemiological and clinical studies

Missing or incomplete phenotypic information can severely deteriorate the statistical power in epidemiological studies. Here we evaluate the ability of Nuclear Magnetic Resonance (^{1}H-NMR) metabolomics (Nightingale Health©, Helsinki, Finland) to reconstruct conventional clinical variables. For this purpose, we trained and evaluated prediction models (**Figure 1A**) for 20 conventional clinical variables (**Figure 1B**) using data of ~31,000 individuals collected within the Dutch Biobanking and BioMolecular resources and Research Infrastructure (BBMRI-NL: https://www.bbmri.nl/). Out of 220 metabolomic variables measured on the platform, we employed 56 metabolic markers, selected to be the most uncorrelated [21], [22] and most successfully measured in the BBMRI studies (**Methods and Supplementary Materials**). Conventional clinical variables were transformed or constructed with the emphasis to be able to capture clinically relevant aspects of disease risk. For instance, we dichotomized continuous variables according to generally accepted clinical thresholds, thus obtaining for each of these clinical variables an 'at risk' [TRUE/FALSE] variable. For the same purpose, some variables were either merged or split. For instance, a sex-specific '*obesity*' [TRUE/FALSE] variable was defined using body mass index, waist circumference and sex, whereas chronological age was split into three categories **(Figure 1B)**. Overall, we were able to construct and evaluate 20 variables mainly representing risk factors of cardio-metabolic health that are routinely assessed in epidemiological and clinical studies.

Logistic Elastic-NET regression models were trained for each of the 20 dichotomous variables, measured in at least 6 of the BBMRI studies, in both healthy and diseased individuals. Model development was performed in two loops to prevent overtraining. An *inner* loop of 5-Fold Cross Validation with 5 repetitions was used to tune the hyperparameters of the

model. Model performances where then evaluated in an *outer* loop of held out data, using again a 5-Fold CV or a Leave-One-Biobank-Out-Validation (LOBOV) (**Figure 1A, Methods**). We assessed model performances using the mean Area Under the Curve (AUC) of the receiver-operator curve obtained in the *outer* 5-Fold CV (**Table 1**) and considered a model's performance to be sufficiently accurate at AUC > 0.7. Overall, 19 out of 20 models passed this criterium, with only a single phenotypic variable, '*high-pressure*', that could not be accurately captured by ^{1}H-NMR ($AUC_{5\text{-Fold CV}} = 0.68$). Strikingly, 9 out of 20 models achieved an $AUC_{5\text{-Fold CV}} > 0.9$. While some of these high performances are expected as they directly relate to metabolic markers assessed on the platform ('*Low eGFR*', '*high triglycerides*', '*high LDL cholesterol*', '*high total cholesterol*', and '*low LDL cholesterol*'), this is not the case for four other high performing models: '*diabetes*' ($AUC_{5\text{-Fold CV}} = 0.94$), '*metabolic syndrome*' ($AUC_{5\text{-Fold CV}} = 0.93$), '*sex*' ($AUC_{5\text{-FoldCV}} = 0.92$), '*lipid medication*' ($AUC_{5\text{-Fold CV}} = 0.90$). Also, other important cardio-metabolic health statuses, including '*obesity*', '*high CRP*' and '*blood pressure lowering medication*' were predicted at a more than satisfactory accuracy ($AUC_{5\text{-Fold CV}} > 0.8$), indicating that overall, the ^{1}H-NMR metabolome can be used to impute a broad spectrum of common clinical variables.

As the performances of our models may vary per biobank due to study-specific characteristics, e.g. varying study inclusion criteria or protocols for sample storage, we also evaluated the variation of our model performances across biobanks. First, using a Leave-One-Biobank-Out-Validation (LOBOV), we evaluate how our models would perform when applied to data of a new unseen biobank. As expected, mean model accuracies of the LOBOV, weighted based on the size of the testing biobank, show more variation across folds (**Figure S2A-B)** and are generally slightly lower than the overall results of the 5-Fold CV (**Table 1**). In particular, some of the smaller studies containing diseased patients showed relatively poor accuracies (**Figure S2B**). Indeed, surrogate values do show cohort specific effects, but

interestingly, this does not necessarily affect its predictive performance within cohorts **(Figure S2C)**. Overall, 14 out of the 20 models performed on average satisfactorily ($AUC_{LOBOV} > 0.7$) across all studies in the LOBOV setting.

Table 1 | Performances of the 20 metabolic predictors

Binary Outcomes (threshold)	**# samples**	**# cohorts**	**# True positives**	**Results (AUC)**	
				5-Fold CV (mean)	**LOBOV** (weighted mean)
Low eGFR (eGFR ≤ 60 ml/min [23])	21,439	23	1,196 (5.6%)	0.99 [0.98-0.99]	0.97 [0.91-0.99]
High triglycerides (trig ≥ 2.3 mmol/L [24])	13,401	11	1,645 (12.3%)	0.97 [0.97-0.98]	0.95 [0.84-0.99]
High LDL cholesterol (LDL ≥ 4.1 mmol/L [24])	13,261	11	2,051 (15.5%)	0.96 [0.96-0.97]	0.97 [0.86-0.98]
High total cholesterol (totchol ≥ 6.2 mmol/L [24])	16,586	11	3,206 (19.3%)	0.96 [0.96-0.96]	0.96 [0.83-0.99]
Low HDL cholesterol (HDL ≤ 1.3 mmol/L [24])	16,506	11	7,414 (44.9%)	0.95 [0.95-0.96]	0.95 [0.85-0.96]
Diabetes (TRUE/FALSE)	18,841	16	4,034 (21.4%)	0.94 [0.93-0.9]	0.86 [0.72-0.98]
Metabolic syndrome (TRUE/FALSE)	7,811	6	3,452 (44.2%)	0.93 [0.92-0.94]	0.86 [0.71-0.93]
Sex (male) (TRUE/FALSE)	21,610	23	10,281 (47.6%)	0.92 [0.92-0.93]	0.91 [0.73-0.99]
Lipid medication (TRUE/FALSE)	17,707	14	5,783 (32.7%)	0.91 [0.90-0.91]	0.85 [0.77-0.94]
Low age (age < 45 y.o.)	21,519	23	3,353 (15.6%)	0.89 [0.88-0.90]	0.80 [0.55-0.85]
High hsCRP (hsCRP > 3mg/L [25])	5,180	8	1,548 (29.9%)	0.86 [0.84-0.86]	0.81 [0.7-0.86]
Blood pressure lowering medication (TRUE/FALSE)	15,832	13	7,234 (45.7%)	0.82 [0.81-0.83]	0.71 [0.51-0.84]
High age (age ≥ 65 y.o.)	21,519	23	8,273 (38.4%)	0.82 [0.80-0.83]	0.73 [0.64-0.86]
Obesity status (BMI ≥30 kg/m^2 and w.c. ≥ 102 cm [M] BMI ≥30 kg/m^2 and w.c. ≥ 93 cm [F] [26])	19,322	18	3,135 (16.2%)	0.78 [0.75-0.80]	0.76 [0.69-0.81]
Low hemoglobin (hgb ≤ 6.67 mmol/L [M]; hgb ≤ 7.62 mmol/L [F] [27])	10,508	6	1,299 (12.4%)	0.76 [0.73-0.78]	0.72 [0.63-0.75]
Low white blood cells (wbc ≤ 4.5x10^9 L [27])	9,496	6	818 (8.6%)	0.73 [0.69-0.76]	0.61 [0.5-0.71]
Current smoking (TRUE/FALSE)	21,662	23	8,276 (38.2%)	0.71 [0.70-0.72]	0.63 [0.48-0.78]
Alcohol consumption (TRUE/FALSE)	16,430	13	11,763 (71.6%)	0.71 [0.70-0.73]	0.60 [0.48-0.70]
Middle age (45 y.o. ≥Age < 65 y.o.)	21,519	23	9,893 (46.0%)	0.71 [0.70-0.72]	0.58 [0.50-0.69]
High pressure (systolic ≥ 140 mmHg and diastolic ≥ 90 mmHg [24])	17,509	12	7,765 (44.3%)	0.68 [0.66-0.69]	0.60 [0.52-0.76]

samples: number of participants; # cohorts: number of cohorts that we could use for training the models and for the evaluation using 5-Fold Cross Validation (5-Fold CV); # TRUE POSITIVES: the number of samples with original variable equal to TRUE; Results (AUC): 5-Fold CV= the mean AUCs of the 5-Fold CV) and LOBOV= the mean AUCs of the Leave One Biobank Out Validation weighted based on the size of the testing biobank. [M]: male, or [F]: female specific criteria, eGFR=estimated glomerular filtration rate, w.c=waist circumference, hgb=haemoglobin, wbc=white blood cells.

Metabolic surrogates show dependencies mimicking the conventional clinical variables

Given that all models are trained on a relatively limited set of metabolic markers, we investigated to what extent the produced models and predictions show mutual dependencies. For this purpose, we first visualized the coefficients (betas) of the logistic Elastic-NETs (**Figure 2**) to show the relative importance of the metabolites within each of the prediction models. While the selection of variables for the models shows a distinct pattern, we also note some similarities, as quantified by the correlations between the model coefficients (**Figure S3**). Overall, we note a clear preference for the models to include metabolites of the classes "Lipoproteins" and "Lipids and related measures" over "Amino Acids". In addition, we note that the models of related phenotypes also display some resemblances in the employed features, for instance '*lipid medication*' and '*blood_pressure_lowering_medication'* share some model characteristics.

We next evaluated correlations between the outputs of our models, from here on referred to as the 'metabolic surrogates' (**Figure 3)** and compared these to correlations between the original clinical variables (**Figure S1B**) in the BBMRI.nl data set. Overall, we observe that the model outputs show correlation patterns and groupings that largely mimic that of the original variables. For instance, model outputs trained on variables related to weight problems, i.e. '*obesity*', '*diabetes*', '*metabolic syndrome*', show high mutual correlations, and moreover are grouped with model outputs trained on medication usage, i.e. '*lipid medication*' and '*blood pressure lowering medication*'. Although we observe some correlations between the outputs of our different age predictors i.e. '*low age*', '*middle age*', '*high age*', we observe that '*high age*' is grouped with the models for '*high hscrp'*, '*lipid medication*' and '*blood pressure lowering medication*', while '*middle age*' is grouped with '*current smoking*' and '*alcohol use*'

and '*low age*' with '*low white blood cell count'*. This suggests that at different ages, different conventional clinical variables play a role in physiology; an aspect well-known from literature [28]–[30]. Overall, this indicates that our models show mutual dependencies similar as we observe for the original clinical variables.



Figure 2: ElasticNETs metabolites relative importance. The heatmap reports the relative importance of the metabolites (columns) in each of the trained models (rows). Prior to visualization, metabolite coefficients were scaled per model by dividing them by the coefficients' sum in each model to create the relative importance per model. Top: Metabolites were then ordered based on the sum of their importance across all models. In addition, the models are clustered on the similarity between relative importance. Bottom: Categorized metabolic measures: "Amino acids", "energy metabolism", "inflammation", "lipoproteins" and "lipids and related measures". Right: Mean AUCs of the 5-FoldCV in a scale of purple.



Figure 3: Heatmap of pairwise correlations of the metabolic based surrogate markers calculated in BBMRI-NL. The heatmap of correlations of the metabolic surrogate values of the 19 successful models, clustered based on the correlation levels, between the imputed metabolic surrogate levels within BBMRI-NL.

Projection in an independent study demonstrates model accuracy

We performed a more extensive evaluation of the surrogate values by employing Nightingale ^{1}H-NMR metabolomics and phenotypic data of the Leiden Longevity Study, a

cohort excluded from the training and testing sets [20]. The Leiden Longevity Study is a two-generation family-based cohort consisting of highly aged parents (LLS-SIBS, 851 individuals, age median = 92 years old) their middle-aged offspring and their partners (LLS-PAROFF, 2,307 individuals, age median = 59 years old). Using our models to project metabolic surrogates in the LLS-PAROFF gave an independent confirmation that conventional clinical variables can be readily captured by ^{1}H-NMR metabolomics. Splitting the surrogate values by the actual labels of the corresponding binary phenotypes generally showed a good separation for important cardio-metabolic variables like '*sex*', '*diabetes status*', '*lipid medication', 'blood_pressure_lowering_medication'* and '*high LDL cholesterol*' (**Figure 4A** and **S4**), emphasizing the suitability of our models for quality control purposes or to impute missing data. For instance, model results for 'sex' could be applied to verify absence of sample mix-ups ($t.stat = 44.58, p = 1.4x10^{-313}$). In addition, surrogate values seem informative on the nature of the missingness of phenotypic data. For instance, participants with a missing diabetes status typically had metabolic surrogate values similar to those of participants without diabetes (diabetes: $\mu_F = 0.05$, $\mu_T = 0.41$, $\mu_{NA} = 0.08$), suggesting that a missing diabetes status generally implies 'non-diabetics' in this cohort. Similar observations were made for medication status (lipidmed: $\mu_F = 0.22$, $\mu_T = 0.45$, $\mu_{NA} = 0.21$ and blood_pressure_lowering_med: $\mu_F = 0.44, \mu_T = 0.55, \mu_{NA} = 0.46$): participants with missing statuses were more similar to non-medication users than medication users. In contrast, participants with missing values in LDL cholesterol had surrogate values indicating "at risk" levels of LDL cholesterol (high_ldl_chol: $\mu_F = 0.07$, $\mu_T = 0.66$, $\mu_{NA} = 0.14$). Lastly, our surrogates also allow for explorative analyses of totally unrecorded variables. For instance, the '*metabolic syndrome*' surrogate indicates participants who are more likely to have metabolic syndrome, a status which was not assessed in the LLS-PAROFF cohort (**Figure 4A)**.

Projection in the Leiden Longevity Study shows associations with additional cardio-metabolic phenotypes

Within the LLS-PAROFF we had access to several additional variables pertaining to one's cardio-metabolic risk namely hormone levels of insulin, leptin, and adiponectin, as well as the levels of the inflammatory marker interleukin 6 (*IL6*) (**Figure 4B**). As expected, insulin levels correlated positively with most surrogate cardio-metabolic risk factors and endpoints, including '*diabetes*' [31] ($r = 0.28, p = 7.6x10^{-42}$) and even more so with *'metabolic syndrome'* ($r = 0.52, p = 1.4x10^{-152}$) [32]. Conversely, both '*low wbc*' and '*low age'* were inversely correlated with insulin, both reflecting the associations with decreased insulin sensitivity in those with high white blood cell counts [33] or in old age [34]. A similar analysis for the satiety hormone leptin showed the strongest positive correlations with *'obesity' [35]* ($r = 0.3, p = 5.6x10^{-49}$), but also with '*high hscrp*'[36] ($r = 0.29, p = 4.2x10^{-46}$). A significant correlation with leptin was also found for *'metabolic syndrome' [37]* ($r = 0.15,\ p = 3.9x10^{-13}$), yet not '*diabetes*' [38] ($r = 0.02, p = 0.33$). In line with previous studies, higher levels of the adiponectin hormone generally correlated with lower values of the surrogates, most prominently with '*low hdlchol*' ($r = -0.47,\ p = 8.6x10^{-123}$) and '*high triglycerides*' ($r = 0.3,\ p = 1.1x10^{-48}$) [39]. Higher adiponectin levels were positively correlated with '*low wbc*'($r = 0.35, p = 6.1x10^{-68}$), reproducing the previously reported association by Matsubara *et al* [40]. Levels of the inflammatory marker IL6 were most prominently positively correlated with the surrogates '*high hscrp' [41]* ($r = 0.31,\ p = 8.7x10^{-51}$), *'current smoking' [42]* ($r = 0.2,\ p = 3.9x10^{-13}$), and inversely correlated with '*low wbc*' [43] ($r = -0.19, p = 3.9x10^{-13}$). When comparing these correlation patterns obtained with the surrogate values (**Figure 4B**) with those you would get when using the original values (**Figure S7A**), we generally notice highly similar trends ($r \sim 0.83$, **Figure S7F**), as exemplified for leptin (**Figure 4C**). Overall, these findings indicate that our metabolic

surrogates faithfully reproduce the original clinical variables in their association with insulin, leptin, adiponectin and IL6.



Figure 4: Metabolic surrogates applied to LLS-PAROFF: [A] Paired boxplots show surrogate values split between the TRUE/FALSE (0/1) in the original values of the clinical variables (*** p value ≤ 0.001). For metabolic syndrome the original variables are entirely missing, so no p-value is reported. **[B]** Heatmap of the correlations between the metabolomic surrogates (columns) and four additional cardio-metabolic biomarkers (rows) available in LLS-PAROFF. Values of insulin, leptin, adiponectin and IL6 were transformed with a natural logarithm. **[C]** Paired bar plots comparing the correlations computed between leptin and the metabolic surrogates (blue) and those computed between leptin and the values of the original clinical variables (red) the surrogates are trained to predict.

Metabolic surrogates to explore confounders in Metabolome Wide Association Studies

We next explored the use of ^{1}H-NMR metabolic surrogates to complement missing phenotypic data in metabolome-wide association studies (MetaboWAS). As an example, we evaluated the association of metabolic markers with Type 2 Diabetes status (T2D) in absence of information on a known potential confounder: BMI. We designed a controlled experiment to evaluate to what extent surrogate 'obesity' can replace BMI, using data of 1,697 individuals of LLS-PAROFF with complete metabolomic, BMI and diabetes status, of which 79 are diagnosed with type 2 diabetes.

First, we ascertained that BMI was indeed a confounder, also within the LLS-PAROFF, by showing that BMI associated with the outcome (Type 2 Diabetes status, *t-test*= -7.83, p = $8.25\text{x}10^{-15}$ **Figure S8A**), as well as many of the determinants (147 significant metabolites

after correction, see **Methods**) of the MetaboWAS. Concomitantly, further adjustment of the MetaboWAS on T2D for BMI drastically reduced the number of significant metabolites. To compare, when adjusting for age and sex we identified 136 metabolites significantly associated with diabetes status, whereas further adjustment for BMI identified 80 significant metabolites (**Figure S9B Comparison 1**). Next, we performed the same association analyses using the '*obesity*' surrogate as confounder. Similar to BMI, also the '*obesity*' surrogate is significantly higher in diabetics as compared to non-diabetics (*t-test* = -11.2, $p = 2.48\text{x}10^{-28}$ **Figure S8B**) and was associated with many of the metabolites (176 significant associations). Further adjusting the MetaboWAS on T2D for '*obesity*' reduced the number of significant metabolites to 66 (**Figure S9B Comparison 2**).

We then investigated to what extent adjusting for BMI or adjusting for the '*obesity*' surrogate yields similar metabolite markers to T2D associations, by comparing the obtained estimates from both models (**Figure 5**). Overall, highly similar ($r^2 = 0.902$) associations between metabolic markers and T2D are found for both models, with glucose being the most significantly associated marker in both ($p = 9.43x10^{-28}$ when correcting for BMI and $p = 1.6x10^{-26}$ correcting for *'obesity'*). While most metabolites reported to be significantly associated with T2D overlap between the two models (62 out of 227; in purple), some discrepancies were observed, particularly at the significance threshold. When correcting for BMI, 18 significant metabolic markers were identified, that were not identified when correcting for '*obesity*' (red dots, false negative rate ~ 0.11). Conversely, 7 metabolites were deemed significantly associated with diabetes status when adjusting for '*obesity*', but not when adjusting for BMI (blue dots, false positive rate ~ 0.027). Nevertheless, overall, the differences in estimated effects remain small, indicating that metabolic surrogates may prove useful to account for missing data in epidemiological studies.



Figure 5: Comparison between the estimated coefficients of metaboWAS on T2D adjusted for BMI or for surrogate *'obesity'*. On the x-axis the metaboWAS for diabetes adjusting for BMI and on the y-axis the metaboWAS for diabetes adjusted for surrogate obesity. The data set composed of 1,697 individuals, 79 of which are diabetics. Estimated coefficients for each metabolite (points) are colored based on their significance in the two models: purple: significant in both; red: significant when adjusted for BMI only; blue: significant when adjusted for surrogate obesity only; black never significant. Lower right corner: a contingency table with the number of significant and non-significant metabolites identified using the two models.

Metabolic surrogates associate with incident all-cause mortality in older individuals

Next, we evaluated whether metabolic surrogates are indicative of health at old age, by associating these with all-cause mortality in a nonagenarian subsample of the Leiden Longevity Study (LLS_SIBS; 844 individuals, median age at baseline: 92 years old) (**Figure 6A**). Using a Cox proportional hazards model adjusted for sex and age at inclusion for each of the 19 metabolic surrogates (**Materials and Methods**), we observed that 13 out of the 19 surrogates associated significantly with all-cause mortality (**Figure 6,** 'all'). In line with previous reports, we observed the largest effect sizes with the surrogate levels of '*high age'*, '*medications usage'*, '*diabetes status'*, '*high hscrp'* and '*hemoglobin'*. As previous studies have reported sex-specific associations for these clinical variables with all-cause mortality, we conducted a stratified analysis [44]–[50]. Although, the direction of association with all-cause mortality remains generally the same between men and women, the strengths and their significance are in some cases different. For instance, the surrogate '*diabetes'* is associated with a higher risk

on mortality in men (HR = 1.23, $p = 6.42\text{x}10^{-4}$), than for women (HR = 1.11, $p = 3.1\text{x}10^{-3}$), the same goes for '*blood pressure lowering medication'* (men: HR = 1.3, $p = 1.13\text{x}10^{-5}$, women: HR = 1.1, $p = 6.39\text{x}10^{-3}$). In contrast, '*low hemoglobin*' is associated with a higher risk in women (HR = 1.5, $p = 1.95\text{x}10^{-13}$), than men (HR = 1.37, FDR = $2.42\text{x}10^{-8}$).

To identify the minimal set of metabolic surrogates independently associating with all-cause mortality, we performed a stepwise (forward/backward) cox regression, adjusted for age at sampling, in the LLS-SIBS dataset (**Figure 7A-B**), stratified for sex. The surrogates '*high hsCRP*' and '*high triglycerides*' emerged as independent predictive features in both male and female models, associated with an increased and decreased risk respectively. While eight surrogates contributed to the male model, including '*lipid medication'*, '*high age*', '*high hsCRP'* and '*low hdlchol'*, only three surrogates contributed to the mortality prediction in females: '*high hsCRP'*, '*high triglycerides'* and *'low hemoglobin'*. These findings are in line with previous reports that different risk factors seem to predict survival up to the highest ages for the different sexes [51]–[53].



Figure 6: Associations of the surrogate metabolic measures with incident all-cause mortality. Associations of the metabolic surrogates with time to all-cause mortality in LLS-SIBS, in groups comprising the entire set ("All", N = 844 with 838 reported deaths), males (N = 326 with 325 reported deaths) or females (N = 518 with 513 reported deaths).

[A]



[B]



Figure 7: Composite metabolomics predictors of incident all-cause mortality: Predictors of time to death for males **[A]** and females **[B]**, in LLS-SIBS, composed using the surrogate metabolic measures, sex and age. "(cluster)" refers to the variable controlling for family relationships (methods)**.** Cox regression models were made using a step forward/backward selection.

Discussion

Missing phenotypic data is common in large epidemiological studies and in particular impedes biomarker research in older individuals. We employed ^{1}H-NMR metabolomics data as a single source of information to successfully impute 19 out of 20 conventional clinical variables that mainly relate to cardio-metabolic health. We highlighted the potential of our imputation models for conventional clinical variables with three application scenarios. First, we applied our models to an independent study, the Leiden Longevity Study, demonstrating that we can reconstruct conventional clinical variables at high accuracy. Secondly, we showed the value of metabolic surrogates in omics studies when data on potential confounders is missing. Finally, we exemplified how metabolic surrogates can be used to explore risk factors of health in older individuals by showing that multiple metabolic surrogates are independently predictive of all-cause mortality.

Using logistic ElasticNET regression models we were able to reconstruct a broad range of conventional clinical variables assessed in BBMRI-NL pertaining to physiological measures, body composition measures, environmental exposures, inflammatory factors, medication usage blood cell composition, lipids metabolism, and also clinical endpoints. For this purpose, we constructed composite variables that may better capture particular aspects of health, for instance, our '*obesity*' variable integrates body mass index, waist circumference and sex to create a sex-specific measure for overweight. In addition, we chose to construct binary representations of the continuous clinical variables for several reasons. First, we binarized continuous variables for a practical reason – to be able to judge all models on the same criteria. Secondly, predicting continuous variables using linear ElasticNET regression models emphasizes the prediction of the extremes of a phenotypic distribution, i.e. the model will fit the most atypical participants, whereas the current approach emphasizes to predict the commonly populated phenotypic range in which participants become at risk. Thirdly, our

366 models output a posterior probability that indicates the likelihood (a continuous score) of a
367 sample belonging to one of two labels, e.g. *obese*/*non-obese*. In effect, these posteriors
368 reconstitute part of the information lost when dichotomizing continues variables, as
369 exemplified by the observed correlation patterns between surrogates that mimic the correlation
370 patterns between the original variables.

371 Our pre-trained models for conventional clinical variables allow for the imputation of
372 missing datapoints in partially incomplete phenotypic variables, and moreover they offer the
373 opportunity to explore associations with completely unobserved phenotypic variables. The
374 latter is very much in line with the current use of PolyGenic Scores (PGSs) [54]–[56]. A PGS
375 captures the genetic propensity of the realization of a particular polygenic phenotype. Nearly a
376 thousand PGSs have been collected [57], which can be used to systematically explore
377 correlations between a measured variable of interest and a wide array of phenotypes-by-proxy
378 in genetic studies. We propose a similar use for metabolic surrogates in large metabolomics
379 studies, yet with two noteworthy distinctions. Whereas PGSs can arguably be used to tease out
380 causality in so-called Mendelian Randomization studies [58], metabolomic surrogates cannot.
381 In contrast, while PGSs often only explain a very modest part of their respective phenotypes,
382 metabolic surrogates explain a much larger part, thus enabling different types of applications.
383 We illustrated this in our second application scenario where we showcased the use of surrogates
384 to explore potential confounding by non-assessed phenotypic variables in omics studies. While
385 use of actual phenotypic variables will always be preferred over metabolic surrogates, the
386 availability of these metabolic surrogates can thus be used to direct replication efforts or to
387 inform the design of new or follow-up studies.

388 Besides anthropometric measures and other physiological characteristics, the blood ^{1}H-
389 NMR metabolome was previously also shown to capture aspects directly pertaining to health
390 outcomes. In particular, we and others have previously reported ^{1}H-NMR metabolomics-based

risk estimators of cardiometabolic disease [59], [60], pneumonia and COVID infection [61], and all-cause mortality [17]. While this clearly illustrates the vast potential of the blood ^{1}H-NMR metabolome as a universal readout for health outcomes, it also raises the question what factors give rise to metabolomic profiles associated with adverse outcomes. Given that the find variation in the ^{1}H-NMR metabolome is the result of a complex interplay of both environmental and genetic factors, we evaluated whether our surrogates might give us a first indication. To do so, we tested which of our surrogates might be indicative of all-cause mortality in an elderly subset of the LLS-study. Intriguingly, by employing our pre-computed models as well as when we built multi-variate cox-regression models for time-to-death, we find metabolic surrogates that relate to conventional clinical risk factors known to associate with mortality risk at old age. Moreover, sex-stratified analyses recapitulate some of the known differences in mortality associations observed at old age, with for instance many more risk factors independently associated for mortality in males, as compared to females. These results illustrate that metabolic surrogates can aid in the interpretation of metabolomics-based risk estimators.

This study has several limitations. LOBOV analyses revealed that the trained surrogates may show study-specific effects that may relate to employed procedures of data collection or sample storage of the cohorts under investigation. While these artifacts may be addressed using batch-correction algorithms [62], or employing deep learning models for the prediction tasks, we note that differences between studies may also be due to valid biological reasons, such as differences in inclusion criteria. Secondly, the number of biomarkers captured by the targeted NMR platform is small compared to the whole human metabolome (over 19,000 according to the Human Metabolome Database [63]). Therefore, more elaborate, though typically more costly, high-throughput platforms might reach even higher accuracy levels. However, employing more biomarkers also has the danger of overfitting to the aforementioned study-related artifacts.

In conclusion, we have shown that the blood metabolome assayed by ^{1}H-NMR metabolomics can successfully capture a broad set of conventional clinical variables opening various possibilities to exploit surrogates of these clinical variables in in large epidemiological and clinical studies.

MATERIALS and METHODS

1. Study populations

The samples used for the current study are part of the BBMRI-NL Consortium (Dutch Biobanking and BioMolecular resources and Research Infrastructure, https://www.bbmri.nl/), which includes the following 28 Dutch biobanks: ALPHAOMEGA, BIOMARCS, CHARM, CHECK, CODAM, CSF, DMS, DZS_WF, ERF, FUNCTGENOMICS, GARP, HELIUS, HOF, LIFELINES, LLS_PARTOFFS, LLS_SIBS, MRS, NESDA, PROSPER, RAAK, RS, STABILITEIT, STEMI_GIPS-III, TACTICS, TOMAAT, UCORBIO, VUMC_ADC, VUNTR. A description of the cohorts included is provided in the Supplementary Materials. Ethics committees approved the protocols for these studies in all the involved institutes, and all participants provided informed consent. The whole data set contains samples of ~31,000 individuals.

2. Metabolomic measurements

The present study included metabolite concentrations measured in EDTA plasma samples using the high-throughput proton Nuclear Magnetic Resonance (^{1}H-NMR) metabolomics (Brainshake Ltd./Nightingale Health©, Helsinki, Finland). This device provides the quantification of routine lipids, lipoprotein subclasses, fatty acid composition and various low-molecular weight metabolites including amino acids, ketone bodies and glycolysis-related metabolites in molar concentration units. Details about the methods and applications of the NMR platform have been provided previously [22], [64]. The total amount of metabolic variables reported is 226 for EDTA plasma samples, including the ratios and derived measurements, but only 63 of these were considered for the current study, to prevent overfitting [21], [59]. The list comprises the total lipid concentrations, fatty acids composition and low-molecular-weight metabolites including ketone bodies, glycolysis-related metabolites, amino-

acids and metabolites related to immunity and fluid balance (See the Supplementary Materials for a full list).

3. Data Pre-processing

a. Pre-processing of metabolomics data

We included in our analyses all the cohorts reporting on all the 63 metabolic biomarkers, therefore we omitted CODAM (N = 254) and VUNTR (N = 3,896), which are missing acetoacetate and glutamine, respectively. We also decided to not consider the metabolites with low detection rates in more than one cohort (3-hydroxybutyrate) or which frequently failed to reach the minimum detection threshold (XL_VLDL_L, XXL_VLDL_L, L_VLDL_L, XL_HDL_L, L_HDL_L). We removed outlier samples with 1 or more missing metabolic measure (232 removed samples), 1 or more zeroes per sample (74 removed samples) and samples with any metabolite concentration level more than 5 standard deviations away from the overall mean per metabolomic variable (604 removed samples). The remaining 551 missing values in the dataset were imputed using the function nipals of the R package pcaMethods, and we z-scaled the metabolic measures across all samples to have comparable concentration levels between metabolites. The final data matrix comprised 26,107 samples across 56 metabolic variables. For more details, see Supplementary Materials. The number of samples used to train a predictor for a clinical variable depended on the number of samples missing this phenotypic information (Table 1). More information about the range of each phenotype within each biobank can be found in the Supplementary Materials.

b. Binarization of the clinical variables

To emphasize the relevant clinical conditions, we used clinical thresholds to obtain dichotomous variables out of the set of the available continuous risk factors, separating

between “normal” and “at risk” levels for each risk factor (in ***Table1*** and in the Supplementary Document 3).

c. Composed clinical variables

We chose to include some composed clinical variables: 1) LDL cholesterol, which was calculated using the Friedewald equation [65] with the measured hdl cholesterol, triglycerides levels and total cholesterol; 2) eGFR (estimated Glomerular Filtration Rate), which is a measure for the kidney filtration rate of an individual, was calculated using the creatinine-based CKD-EPI equation [66]; 3) obesity, which is a binary variable describing if a person is clinically obese or not variable that uses BMI, waist circumference and sex based on the fniding of Flint et al. [26]; 4) high pressure, a binary variables which defines high blood pressure by using systolic and diastolic blood pressure [24]; 5) low_hgb (low hemoglobin), which is a binary variables describing ‘at risk’ levels of hemoglobin by using hemoglobin and sex [27].

4. Estimation of the metabolic surrogates

a. Method selection

The models considered for each Risk Factor are logistic regression models:

$$\hat{c}_i \sim \beta_0 + \sum_{j=1}^{56} \beta_j m_j \, \beta_1 + \varepsilon_i$$

in which c_i represent one of clinical variables of interest, m_j one of the 56 measured metabolites, β_j the regression coefficient, and ε_i the normal distributed reconstruction error. The regression coefficients are found by minimizing the ordinary least squares error, with the addition of an elastic net regularization term for the coefficients:

$$\boldsymbol{\beta}(\alpha, \lambda) = argmin_{\beta}((c_i - \hat{c}_i)^2 + \lambda[\alpha \|\boldsymbol{\beta}\|_1 + (1-\alpha)\|\boldsymbol{\beta}\|_2])$$

in which λ ($\in (0, \infty)$) represents the “shrinkage parameter” and α ($\in (0,1)$) is the mixing parameter balancing the L1 and L2 norm regularizations. We fixed the mixing parameter α at

0.5 for the predictive models, like previously done by other authors and optimized the shrinkage parameter using an inner-fold cross-validation scheme.

b. Training and validation procedure

We employed two training-evaluation procedures to get an unbiased estimate of the models' possible performances (Figure 1). As a first scenario, we used a Double 5-Fold-Cross-Validation (5-Fold CV) with 5 repetitions. This procedure consists of two loops of 5FCV, one internal and one external, in which we first split the dataset in testing (20%) and training (80%) sets and then on the latter set we have another 5FCV repeated for 5 different times, which is done for an unbiased tuning of the model (setting the correct λ parameter) that is finally trained on the complete training dataset and tested on the left-out test data. Both 5-FoldCVs were done such that the original distribution of each clinical variable is maintained as much as possible (using the function *createFolds* from the R package *caret*). In the second training-testing procedure, we applied a Leave-One-Biobank-Out-Validation (LOBOV), which consists of holding out one of the biobanks with the considered variable available, which is then used as a test set, while training on the remaining biobanks [16]. Also, in this setting, we applied a 5FCV with 5 repetitions to tune the best model for each training set.

5. Metabolome wide association studies

We conducted Metabolome Wide Association Studies (MetaboWAS) using the middle-aged cohort of the Leiden Longevity Study (LLS-PARTOFFs, 2,307 individuals, median age at baseline = 59 years old). As metabolites distributions are often skewed, we first transformed all metabolite measurements using a rank inverse normalization (RIN). Applying a PCA on the LLS-PARTOFFs dataset revealed that the first 40 principal components explain 99% of the variance in the metabolites (**Figure S9A**). Hence, the *p-value* of the MetaboWASes were

Bonferroni corrected using 40 tests, i.e. a *p-value* designated significant when smaller than 0.00125 (0.05/40) [60]. We performed 5 different MetaboWASs.

6. Associations of the metabolic surrogates to all-cause mortality

We used Cox proportional hazards models with follow-up time as the time scale, to test for associations between the metabolic surrogate measures and incident endpoints, i.e. all-cause-mortality in LLS-SIBS. We checked for associations adjusting for age and sex. To avoid bias due to familial correlations from pedigrees, we used robust standard errors (calculated with the Huber sandwich estimator) implemented in R coxph function. Considering that the population in LLS-SIBS has a different inclusion criterium for men (age > 89 years old) and women (age > 91 years old), we also evaluated associations separately in men and women. *P-values* were corrected using Benjamini Hochberg separately for each selection (all individuals, men and women) and considered significant the FDR < 0.05. To select potentially interesting metabolic surrogate, we used a stepwise procedure for the Cox regression models, corrected for sex and age. Starting from a model containing the full set of available variables, we removed or added an unselected metabolic surrogate at each round based on the improvement on the model calculated from the Akaike Information Criterion and considering the *p*-value of each variable included in the model.

Acknowledgements

This work was performed within the framework of the BBMRI Metabolomics Consortium funded by BBMRI-NL (a research infrastructure financed by the Dutch government, NWO 184.021.007 and 184.033.111), by X-omics (NWO 184.034.019), VOILA (ZonMW 457001001) and Medical Delta (scientific program METABODELTA: Metabolomics for clinical advances in the Medical Delta). EvdA is funded by a personal grant of the Dutch

549 Research Council (NWO; VENI: 09150161810095). A full list of acknowledgements for all
550 the contributing studies can be found in the Supplementary Material table S1.

551

552 Authors Contribution

553 EbvDA, DB, MJTR and PES conceived and wrote the manuscript. DB performed the analyses.
554 EBvDA and MJTR verified and supervised the analyses. All authors discussed the results and
555 contributed to the final manuscript.

556

557 Competing interests

558 The authors declare that there are no competing interests.

559

560 References

561 [1] K. Strimbu and J. A. Tavel, 'What are Biomarkers?', *Curr. Opin. HIV AIDS*, vol. 5, no.
562 6, pp. 463–466, Nov. 2010, doi: 10.1097/COH.0b013e32833ed177.
563 [2] R. Mayeux, 'Biomarkers: Potential uses and limitations', *NeuroRX*, vol. 1, no. 2, pp. 182–
564 188, Apr. 2004, doi: 10.1602/neurorx.1.2.182.
565 [3] S. Naylor, 'Biomarkers: current perspectives and future prospects', *Expert Rev. Mol.*
566 *Diagn.*, vol. 3, no. 5, pp. 525–529, Sep. 2003, doi: 10.1586/14737159.3.5.525.
567 [4] S. G. Liao *et al.*, 'Missing value imputation in high-dimensional phenomic data:
568 imputable or not, and how?', *BMC Bioinformatics*, vol. 15, no. 1, p. 346, Nov. 2014, doi:
569 10.1186/s12859-014-0346-6.
570 [5] A. Dahl *et al.*, 'A multiple-phenotype imputation method for genetic studies', *Nat. Genet.*,
571 vol. 48, no. 4, Art. no. 4, Apr. 2016, doi: 10.1038/ng.3513.
572 [6] K. T. Do *et al.*, 'Characterization of missing values in untargeted MS-based metabolomics
573 data and evaluation of missing data handling strategies', *Metabolomics*, vol. 14, no. 10,
574 2018, doi: 10.1007/s11306-018-1420-2.
575 [7] M. J. Azur, E. A. Stuart, C. Frangakis, and P. J. Leaf, 'Multiple imputation by chained
576 equations: what is it and how does it work?', *Int. J. Methods Psychiatr. Res.*, vol. 20, no.
577 1, pp. 40–49, Feb. 2011, doi: 10.1002/mpr.329.
578 [8] M. R. Malarvizhi and D. A. S. Thanamani, *K-Nearest Neighbor in Missing Data*
579 *Imputation*.
580 [9] S. Cheng *et al.*, 'Potential Impact and Study Considerations of Metabolomics in
581 Cardiovascular Health and Disease A Scientific Statement From the American Heart
582 Association', *Circ. Cardiovasc. Genet.*, vol. 10, no. 2, Apr. 2017, doi:
583 10.1161/HCG.0000000000000032.

[10] J. Liu *et al.*, 'Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas', *Nat. Med.*, vol. 26, no. 1, pp. 110–117, Jan. 2020, doi: 10.1038/s41591-019-0722-x.
[11] L. M. 't Hart *et al.*, 'Blood Metabolomic Measures Associate With Present and Future Glycemic Control in Type 2 Diabetes', *J. Clin. Endocrinol. Metab.*, vol. 103, no. 12, pp. 4569–4579, Dec. 2018, doi: 10.1210/jc.2018-01165.
[12] G. L. J. Onderwater *et al.*, 'Large-scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine', *Neurology*, vol. 92, no. 16, pp. e1899–e1911, Apr. 2019, doi: 10.1212/WNL.0000000000007313.
[13] I. C. van den Munckhof *et al.*, 'Microbial Impact on Plasma Metabolites is Linked to the Cardiovascular Risk and Phenotypes', *Atheroscler. Suppl.*, vol. 32, pp. 118–119, Jun. 2018, doi: 10.1016/j.atherosclerosissup.2018.04.366.
[14] D. Vojinovic *et al.*, 'Metabolic profiling of intra- and extracranial carotid artery atherosclerosis', *Atherosclerosis*, vol. 272, pp. 60–65, May 2018, doi: 10.1016/j.atherosclerosis.2018.03.015.
[15] J. Tynkkynen *et al.*, 'Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: A prospective study in eight cohorts', *Alzheimers Dement.*, vol. 14, no. 6, pp. 723–733, 2018, doi: https://doi.org/10.1016/j.jalz.2018.01.003.
[16] van den Akker Erik B. *et al.*, 'Metabolic Age Based on the BBMRI-NL 1H-NMR Metabolomics Repository as Biomarker of Age-related Disease', *Circ. Genomic Precis. Med.*, vol. 0, no. 0, doi: 10.1161/CIRCGEN.119.002610.
[17] J. Deelen *et al.*, 'A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals', *Nat. Commun.*, vol. 10, no. 1, pp. 1–8, Aug. 2019, doi: 10.1038/s41467-019-11311-9.
[18] J. E. Ho *et al.*, 'Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes', *PloS One*, vol. 11, no. 2, p. e0148361, 2016, doi: 10.1371/journal.pone.0148361.
[19] M. J. Rist *et al.*, 'Metabolite patterns predicting sex and age in participants of the Karlsruhe Metabolomics and Nutrition (KarMeN) study', *PLoS ONE*, vol. 12, no. 8, Aug. 2017, doi: 10.1371/journal.pone.0183228.
[20] M. Schoenmaker *et al.*, 'Evidence of genetic enrichment for exceptional survival using a family approach: the Leiden Longevity Study', *Eur. J. Hum. Genet.*, vol. 14, no. 1, Art. no. 1, Jan. 2006, doi: 10.1038/sj.ejhg.5201508.
[21] P. Würtz *et al.*, 'Metabolic Signatures of Adiposity in Young Adults: Mendelian Randomization Analysis and Effects of Weight Change', *PLoS Med.*, vol. 11, no. 12, Dec. 2014, doi: 10.1371/journal.pmed.1001765.
[22] P. Soininen, A. J. Kangas, P. Würtz, T. Suna, and M. Ala-Korpela, 'Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics', *Circ. Cardiovasc. Genet.*, vol. 8, no. 1, pp. 192–206, Feb. 2015, doi: 10.1161/CIRCGENETICS.114.000216.
[23] S. A. Williams *et al.*, 'Plasma protein patterns as comprehensive indicators of health', *Nat. Med.*, vol. 25, no. 12, pp. 1851–1857, Dec. 2019, doi: 10.1038/s41591-019-0665-2.
[24] E. Crimmins, S. Vasunilashorn, J. K. Kim, and D. Alley, 'BIOMARKERS RELATED TO AGING IN HUMAN POPULATIONS', *Adv. Clin. Chem.*, vol. 46, pp. 161–216, 2008.
[25] L. M. Biasucci, CDC, and AHA, 'CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper',

633 *Circulation*, vol. 110, no. 25, pp. e560-567, Dec. 2004, doi:
634 10.1161/01.CIR.0000148983.88334.80.
635 [26] A. J. Flint *et al.*, 'Body mass index, waist circumference, and risk of coronary heart
636 disease: a prospective study among men and women', *Obes. Res. Clin. Pract.*, vol. 4, no.
637 3, pp. e171–e181, 2010, doi: 10.1016/j.orcp.2010.01.001.
638 [27] L. Dean and L. Dean, *Blood Groups and Red Cell Antigens*. National Center for
639 Biotechnology Information (US), 2005.
640 [28] R. J. Glassock and C. Winearls, 'Ageing and the Glomerular Filtration Rate: Truths and
641 Consequences', *Trans. Am. Clin. Climatol. Assoc.*, vol. 120, pp. 419–428, 2009.
642 [29] E. Pinto, 'Blood pressure and ageing', *Postgrad. Med. J.*, vol. 83, no. 976, pp. 109–114,
643 Feb. 2007, doi: 10.1136/pgmj.2006.048371.
644 [30] C. M. Schubert *et al.*, 'Lipids, lipoproteins, lifestyle, adiposity and fat-free mass during
645 middle age: the Fels Longitudinal Study', *Int. J. Obes.*, vol. 30, no. 2, Art. no. 2, Feb.
646 2006, doi: 10.1038/sj.ijo.0803129.
647 [31] V. Saini, 'Molecular mechanisms of insulin resistance in type 2 diabetes mellitus', *World
648 J. Diabetes*, vol. 1, no. 3, pp. 68–75, Jul. 2010, doi: 10.4239/wjd.v1.i3.68.
649 [32] C. K. Roberts, A. L. Hevener, and R. J. Barnard, 'Metabolic Syndrome and Insulin
650 Resistance: Underlying Causes and Modification by Exercise Training', *Compr. Physiol.*,
651 vol. 3, no. 1, pp. 1–58, Jan. 2013, doi: 10.1002/cphy.c110062.
652 [33] 'High White Blood Cell Count Is Associated With a Worsening of Insulin Sensitivity and
653 Predicts the Development of Type 2 Diabetes | Diabetes'.
654 https://diabetes.diabetesjournals.org/content/51/2/455 (accessed Feb. 09, 2021).
655 [34] D. C. Muller, D. Elahi, J. D. Tobin, and R. Andres, 'The effect of age on insulin resistance
656 and secretion: a review', *Semin. Nephrol.*, vol. 16, no. 4, pp. 289–298, Jul. 1996.
657 [35] P. J. Enriori, A. E. Evans, P. Sinnayah, and M. A. Cowley, 'Leptin Resistance and
658 Obesity', *Obesity*, vol. 14, no. S8, pp. 254S-258S, 2006, doi:
659 https://doi.org/10.1038/oby.2006.319.
660 [36] O. Ukkola and Y. A. Kesäniemi, 'Leptin and high-sensitivity C-reactive protein and their
661 interaction in the metabolic syndrome in middle-aged subjects', *Metabolism*, vol. 56, no.
662 9, pp. 1221–1227, Sep. 2007, doi: 10.1016/j.metabol.2007.04.019.
663 [37] P. W. Franks *et al.*, 'Leptin Predicts a Worsening of the Features of the Metabolic
664 Syndrome Independently of Obesity', *Obes. Res.*, vol. 13, no. 8, pp. 1476–1484, 2005,
665 doi: https://doi.org/10.1038/oby.2005.178.
666 [38] M. I. Schmidt *et al.*, 'Leptin and incident type 2 diabetes: risk or protection?',
667 *Diabetologia*, vol. 49, no. 9, pp. 2086–2096, Sep. 2006, doi: 10.1007/s00125-006-0351-
668 z.
669 [39] E. Nigro *et al.*, 'New insight into adiponectin role in obesity and obesity-related diseases',
670 *BioMed Res. Int.*, vol. 2014, p. 658913, 2014, doi: 10.1155/2014/658913.
671 [40] M. Matsubara, K. Namioka, and S. Katayose, 'Decreased plasma adiponectin
672 concentrations in women with low-grade C-reactive protein elevation', *Eur. J.
673 Endocrinol.*, vol. 148, no. 6, pp. 657–662, Jun. 2003, doi: 10.1530/eje.0.1480657.
674 [41] T. B. Harris *et al.*, 'Associations of elevated Interleukin-6 and C-Reactive protein levels
675 with mortality in the elderly∗∗Access the "Journal Club" discussion of this paper at
676 http:/www.elsevier.com/locate/ajmselect/', *Am. J. Med.*, vol. 106, no. 5, pp. 506–512,
677 May 1999, doi: 10.1016/S0002-9343(99)00066-2.
678 [42] J. Helmersson, A. Larsson, B. Vessby, and S. Basu, 'Active smoking and a history of
679 smoking are associated with enhanced prostaglandin F2α, interleukin-6 and F2-
680 isoprostane formation in elderly men', *Atherosclerosis*, vol. 181, no. 1, pp. 201–207, Jul.
681 2005, doi: 10.1016/j.atherosclerosis.2004.11.026.

[43] C. E. Byrne, A. Fitzgerald, C. P. Cannon, D. J. Fitzgerald, and D. C. Shields, 'Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes', *BMC Med. Genet.*, vol. 5, no. 1, p. 13, Jun. 2004, doi: 10.1186/1471-2350-5-13.
[44] Y. Wang *et al.*, 'Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants', *BMC Med.*, vol. 17, no. 1, p. 136, Jul. 2019, doi: 10.1186/s12916-019-1355-0.
[45] K. M. Dale, C. I. Coleman, S. A. Shah, A. A. Patel, J. Kluger, and C. M. White, 'Impact of gender on statin efficacy', *Curr. Med. Res. Opin.*, vol. 23, no. 3, pp. 565–574, Mar. 2007, doi: 10.1185/030079906X167516.
[46] Y. An, J. Jang, S. Lee, S. Moon, and S. K. Park, 'Sex-specific Associations Between Serum Hemoglobin Levels and the Risk of Cause-specific Death in Korea Using the National Health Insurance Service-National Health Screening Cohort (NHIS HEALS)', *J. Prev. Med. Public Health Yebang Uihakhoe Chi*, vol. 52, no. 6, pp. 393–404, Nov. 2019, doi: 10.3961/jpmph.19.146.
[47] E. Prescott *et al.*, 'Mortality in women and men in relation to smoking', *Int. J. Epidemiol.*, vol. 27, no. 1, pp. 27–32, Feb. 1998, doi: 10.1093/ije/27.1.27.
[48] P. Muennig, E. Lubetkin, H. Jia, and P. Franks, 'Gender and the Burden of Disease Attributable to Obesity', *Am. J. Public Health*, vol. 96, no. 9, pp. 1662–1668, Sep. 2006, doi: 10.2105/AJPH.2005.068874.
[49] B. T. Palmisano, L. Zhu, R. H. Eckel, and J. M. Stafford, 'Sex differences in lipid and lipoprotein metabolism', *Mol. Metab.*, vol. 15, pp. 45–55, May 2018, doi: 10.1016/j.molmet.2018.05.008.
[50] Y. Li *et al.*, 'Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis', *Atherosclerosis*, vol. 259, pp. 75–82, Apr. 2017, doi: 10.1016/j.atherosclerosis.2017.02.003.
[51] J. Liang, J. M. Bennett, H. Sugisawa, E. Kobayashi, and T. Fukaya, 'Gender differences in old age mortality: roles of health behavior and baseline health status', *J. Clin. Epidemiol.*, vol. 56, no. 6, pp. 572–582, Jun. 2003, doi: 10.1016/s0895-4356(03)00060-x.
[52] M. A. Davis, J. M. Neuhaus, D. J. Moritz, D. Lein, J. D. Barclay, and S. P. Murphy, 'Health behaviors and survival among middle-aged and older men and women in the NHANES I Epidemiologic Follow-up Study', *Prev. Med.*, vol. 23, no. 3, pp. 369–376, May 1994, doi: 10.1006/pmed.1994.1051.
[53] Y. Zhang *et al.*, 'Gender difference in cardiovascular risk factors in the elderly with cardiovascular disease in the last stage of lifespan: The PROTEGER study', *Int. J. Cardiol.*, vol. 155, no. 1, pp. 144–148, Feb. 2012, doi: 10.1016/j.ijcard.2011.09.073.
[54] F. Dudbridge, 'Power and Predictive Accuracy of Polygenic Risk Scores', *PLoS Genet.*, vol. 9, no. 3, Mar. 2013, doi: 10.1371/journal.pgen.1003348.
[55] C. M. Lewis and E. Vassos, 'Prospects for using risk scores in polygenic medicine', *Genome Med.*, vol. 9, Nov. 2017, doi: 10.1186/s13073-017-0489-y.
[56] A. V. Khera *et al.*, 'Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations', *Nat. Genet.*, vol. 50, no. 9, Art. no. 9, Sep. 2018, doi: 10.1038/s41588-018-0183-z.
[57] S. A. Lambert *et al.*, 'The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation', *Nat. Genet.*, pp. 1–6, Mar. 2021, doi: 10.1038/s41588-021-00783-5.

[58] T. G. Richardson, S. Harrison, G. Hemani, and G. Davey Smith, 'An atlas of polygenic risk score associations to highlight putative causal relationships across the human phenome', *eLife*, vol. 8, doi: 10.7554/eLife.43657.
[59] P. Würtz *et al.*, 'Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts', *Circulation*, vol. 131, no. 9, pp. 774–785, Mar. 2015, doi: 10.1161/CIRCULATIONAHA.114.013116.
[60] A. V. Ahola-Olli *et al.*, 'Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts', *Diabetologia*, vol. 62, no. 12, pp. 2298–2309, 2019, doi: 10.1007/s00125-019-05001-w.
[61] Nightingale Health UK Biobank Initiative, H. Julkunen, A. Cichońska, P. E. Slagboom, and P. Würtz, 'Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population', *eLife*, vol. 10, p. e63033, May 2021, doi: 10.7554/eLife.63033.
[62] W. E. Johnson, C. Li, and A. Rabinovic, 'Adjusting batch effects in microarray expression data using empirical Bayes methods', *Biostatistics*, vol. 8, no. 1, pp. 118–127, Jan. 2007, doi: 10.1093/biostatistics/kxj037.
[63] D. S. Wishart *et al.*, 'HMDB 4.0: the human metabolome database for 2018', *Nucleic Acids Res.*, vol. 46, no. Database issue, pp. D608–D617, Jan. 2018, doi: 10.1093/nar/gkx1089.
[64] P. Würtz, A. J. Kangas, P. Soininen, D. A. Lawlor, G. Davey Smith, and M. Ala-Korpela, 'Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies', *Am. J. Epidemiol.*, vol. 186, no. 9, pp. 1084–1096, Nov. 2017, doi: 10.1093/aje/kwx016.
[65] W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, 'Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge', *Clin. Chem.*, vol. 18, no. 6, pp. 499–502, Jun. 1972, doi: 10.1093/clinchem/18.6.499.
[66] Carrero Juan Jesus, Andersson Franko Mikael, Obergfell Achim, Gabrielsen Anders, and Jernberg Tomas, 'hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare-Based Study', *J. Am. Heart Assoc.*, vol. 8, no. 11, p. e012638, Jun. 2019, doi: 10.1161/JAHA.119.012638.